Prevascar

Prevascar (INN: Ilodecakin) is a therapeutic formulation of human recombinant Interleukin 10 (IL–10) and is an important modulator of the inflammatory response.

Renovo has previously reported a positive exploratory efficacy trial for Prevascar in the reduction of scarring in the skin. Following improvements in the manufacturing of Prevascar drug substance and product and identification of a clinical cohort who are predicted (on the basis of a non-drug experimental surgery study) to benefit particularly well from Prevascar’s modulatory effect on the wound inflammatory response, Renovo plans to initiate a new proof of concept clinical trial in skin incisions and excisions in African Ancestral Group volunteers in Q2 2010.